18 January 2018
IntegraGen today announced the launch of SIRIUS™ and MERCURY™, two separate Big Data SaaS tools which enable the extensive exploration of large scale genomic data to assist in the diagnosis and management of patients.
Click here to view press release.
09 January 2018
09 January 2018
IntegraGen and GoPath Laboratories announced today the signing of a non-exclusive licensing agreement allowing GoPath to develop and provide a test based on IntegraGen’s proprietary miR-31-3p biomarker to physicians in the United States and Canada. The test will complement GoPath’s specialized molecular diagnostic testing portfolio for cancer and enable clinicians to (…) »
30 October 2017
IntegraGen today announced that it received the 2017 Galien MedStartUp award for “Best Collaboration for a Breakthrough Therapy or Diagnosis” during the recent MedStartUp Days conference held in New York City. IntegraGen was presented the award based on its collaboration with The Solution Lab, a non-profit organization which (…) »
09 October 2017
IntegraGen announces that results from an analysis of miR-31-3p expression in tumor samples from patients enrolled in the NEW EPOC clinical trial have been published online in Oncotarget. The paper entitled “Association between miR-31- 3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a (…) »
28 September 2017
07 September 2017
IntegraGen today announced the CE-IVD marking and commercial launch of its miRpredX 31-3p test kit in the E.U., the first positive theranostic test for patients with metastatic colorectal cancer.
Click here for press release
28 April 2017
21 April 2017
IntegraGen has announced its financial results for the year ending December 31, 2016. The financial statements were validated by the Company’s Board of Directors on April 20, 2017.
Link to press release
08 March 2017
IntegraGen SA and Laboratoire CERBA announced the signing of a licensing agreement allowing Laboratoire CERBA to develop and provide a test based on IntegraGen’s proprietary miR-31-3p biomarker to prescribing clinicians in France, Benelux, Middle East and Africa. Laboratoire CERBA will develop this test to complement its existing portfolio (…) »